new Delhi: The Seram Institute of India (SII) said on Saturday that human trials of Astrazenka would resume after approval from the Drug Controller General of India (DCGI). The drug company AstraZeneca reported on Saturday that Oxford’s vaccine AZD1222 has become a human test after being approved by the Medicines Health Regulatory Authority (MHRA) in the UK. And MHRA has called the test safe.
SII AstraZeneca will start re-testing
SII said in a statement, “We will reinstate the test after getting approval from DCGI. “SII Chief Executive Officer Bhavna Poonawalla said,” As I said earlier, until the trials are over, we should. No conclusions should be drawn. The series of recent events are a clear example of why we should not be biased and respect the process until the end. ‘
Will test after approval from DCGI
Let me tell you that before the test was administered on humans, there was an adverse effect on a participant involved in the trial. After which the test had to be stopped. After the case was uncovered, DCGI ordered SII to halt the new recruitment for the second and third phase of the vaccine until further orders. AstraZeneca and Oxford said on Saturday that it could not disclose additional medical information, but did say that independent investigators confirmed that the test was safe to resume.
Does green light also reduce migraine problem? University of Arizona scientists did research
So far, 9.24 lakh corona patients died in the world, 52% died in 4 countries, see the list of top 10 natural countries